DECISION MEDICINE
LIVE

Serial Number

97441959

Owner

Pillar Biosciences, Inc.

Attorney

Andrew T. Pettit

First Use Date

Sep 9, 2025

Filing Date

Jun 3, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DECISION MEDICINE Trademark

Serial Number: 97441959

DECISION MEDICINE is a trademark filed by Pillar Biosciences, Inc. on June 3, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Pillar Biosciences, Inc. (17 trademarks)

Natick, MA 01760

Entity Type: 03

Trademark Details

Filing Date

June 3, 2022

Registration Date

Not Registered

First Use Anywhere

September 9, 2025

First Use in Commerce

September 9, 2025

Published for Opposition

June 13, 2023

Goods & Services

Providing localized nucleic acid sequencing for more actionable data to inform healthcare decisions; providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of diagnostics; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; consulting services for medical purposes, health and wellness assessment services; providing health and wellness information; medical services, namely, diagnostic testing for the presence of cancer molecules and molecules indicative of other diseases in bodily fluids; diagnostic testing relating to human health; medical testing services relating to the screening, diagnosing, treating, and monitoring for recurrence of disease; selecting therapies for disease treatment and management; developing companion diagnostics (CDx) for disease treatment and management; management services, namely, management of medical information learned through nucleic acid sequencing, including next-generation sequencing (NGS), and information gathered through analysis of the medical information

Downloadable software for the collection, management, and analysis of data acquired through nucleic acid sequencing, including next-generation sequencing (NGS), to inform healthcare decisions; downloadable software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for analyzing biological samples; downloadable software for analyzing biological samples for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; downloadable software for use with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; downloadable software for health and wellness assessment, namely, for use in genomic analysis; downloadable software for genetic and bioinformatics analysis; downloadable software for testing deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules for research purposes; downloadable software for testing DNA and RNA molecules for diagnostic purposes; downloadable software for use in the fields of nucleic acid sequencing, genotyping, scientific research, clinical research, diagnostics research, and diagnostics; downloadable software for bioinformatics analysis of information derived through NGS; downloadable software for discovering and monitoring indicators of disease through analysis of sequencing data; downloadable software for detecting the presence and prevalence of cancer molecules and molecules indicative of other diseases through analysis of sequencing data; downloadable software for selecting appropriate therapies for disease treatment and management; downloadable software for developing companion diagnostics (CDx) for disease treatment and management

Software as a service (SaaS), namely, hosting non-downloadable software for use by others for collecting, managing, and analyzing data acquired through nucleic acid sequencing, including next-generation sequencing (NGS), to inform healthcare decisions; SaaS, namely, hosting non-downloadable software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, diagnostic research, and diagnostics; SaaS, namely, hosting non-downloadable software for use by others for analyzing biological samples; SaaS, namely, hosting non-downloadable software for use by others for analyzing biological samples for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; SaaS, namely, hosting non-downloadable software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; SaaS, namely, hosting non-downloadable software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; SaaS, namely, hosting non-downloadable software for health and wellness assessment, namely, for genomic analysis; SaaS, namely, hosting non-downloadable software for genetic and bioinformatics analysis; SaaS, namely, hosting non-downloadable software for selecting appropriate therapies for disease treatment and management; SaaS, namely, hosting non-downloadable software for developing companion diagnostics (CDx) for disease treatment and management; bioinformatics services, namely, product research and development in the field of bioinformatics; data processing services for medical, clinical, and scientific purposes; developing diagnostic testing models for others for medical, clinical, and scientific purposes; genetic testing for scientific research purposes; scientific consulting relating to scientific research; scientific services, namely, detection and analysis of cancer molecules and molecules indicative of other diseases in bodily fluids; scientific, clinical, and diagnostic research in the field of bioinformatics; scientific, clinical, and diagnostic research in the fields of disease detection and management; scientific, clinical, and diagnostic research in the fields of cancer discovery, cancer management, and therapy efficacy

Data processing services for medical, clinical, and scientific purposes; data processing services, namely, analysis of sequencing data to detect the presence and prevalence of cancer molecules and molecules indicative of other diseases; management services, namely, management of business information and insights learned through analysis of the information relating to therapeutic medicine marketability

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 25, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jul 25, 2026 GNRT
SU - NON-FINAL ACTION - WRITTEN
Jul 25, 2026 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Jun 3, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 3, 2026 AITU
USE AMENDMENT FILED
Feb 6, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 6, 2026 EISU
SOU TEAS EXTENSION RECEIVED
Feb 6, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2025 EXRA
SOU EXTENSION 4 GRANTED
Aug 8, 2025 EX4G
SOU EXTENSION 4 FILED
Aug 8, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 8, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jan 13, 2025 EX3G
SOU EXTENSION 3 FILED
Jan 13, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 13, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 30, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 30, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 30, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 30, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 3, 2024 EXRA
SOU EXTENSION 1 GRANTED
Feb 1, 2024 EX1G
SOU EXTENSION 1 FILED
Feb 1, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 1, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 8, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 13, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 13, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 24, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 10, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
May 9, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 9, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
May 9, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 9, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 26, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 13, 2022 NWOS
NEW APPLICATION ENTERED
Jun 7, 2022 NWAP